[Organ-preserving treatment in inoperable patients with primary oral and oropharyngeal carcinoma: chances and limitations]
- PMID: 16604330
- DOI: 10.1007/s10006-006-0684-2
[Organ-preserving treatment in inoperable patients with primary oral and oropharyngeal carcinoma: chances and limitations]
Abstract
Introduction: The aim of this study was to demonstrate the chances of nonoperative therapy in those patients from an unselected population suffering from primary previously untreated squamous cell carcinomas of the oral cavity and the oropharynx who did not seem to be operable.
Patients and methods: Following interdisciplinary counseling and extensive individual discussion, 72 (21%) of 340 consecutive patients (1997-2004) did not or did not reasonably seem to be operable; three other patients with stage II disease refused surgery. Of the inoperable patients, 95%suffered from far-advanced stage IV disease, 8% had distant metastases, 14% had synchronous malignancies, 9% were aged over 85 years combined with advanced malignant disease, and nearly 50% were limited in their activity or were even bedridden. Depending on fitness and tumor extent, three therapy regimens were used: intra-arterial (i.a.) high-dose chemotherapy with systemic antagonization for palliation, induction with this i.a. high-dose chemotherapy followed by additional radiotherapy, and induction with the i.a. high-dose chemotherapy followed by additional radiochemotherapy.
Results: Thirty-two patients were treated with i.a. chemotherapy alone for palliation with few acute side effects. The response rate was 34%, and a further growth of the tumour could be inhibited in 49%. The 1- and 2-year survival rates were 21 and 14%, respectively. The three patients who refused surgery experienced complete clinical remission and survived 8, 6, and 2 years, respectively, to date. Twenty-three patients were fit enough to receive additional radiotherapy, and 17 an additional radiochemotherapy. Of the patients, 22% had to cut short additional radiotherapy and 47% had to discontinue concomitant chemotherapy. The 1- and 2-year survival rates were 41 and 25%, respectively; 14 of these irradiated patients experienced long-lasting complete clinical remission >2 years.
Conclusion: About 20% of the patients classified as inoperable could achieve long-lasting remission. Viewed with caution, sex (male), performance state (ECOG) <3, and positive response to i.a. chemotherapy could be regarded as predictors for therapeutic success. The combination of i.a. chemotherapy and radiochemotherapy seemed to be most successful. Conversely, the therapies offered could not achieve a substantial improvement of survival in 80% of patients classified as inoperable; the most successful therapy combination could be offered to merely 23% of patients as classified inoperable due to reduced general condition. The i.a. high-dose chemotherapy has to be regarded as a well tolerated and effective palliation. This descriptive analysis must be followed by specific studies to establish clinical treatment recommendations.
Similar articles
-
Intra-arterial high-dose chemotherapy with cisplatin as part of a palliative treatment concept in oral cancer.AJNR Am J Neuroradiol. 2005 Aug;26(7):1804-9. AJNR Am J Neuroradiol. 2005. PMID: 16091533 Free PMC article. Clinical Trial.
-
Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.J Craniomaxillofac Surg. 2002 Apr;30(2):112-20. doi: 10.1054/jcms.2002.0283. J Craniomaxillofac Surg. 2002. PMID: 12069515 Clinical Trial.
-
Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases.Strahlenther Onkol. 2011 May;187(5):292-9. doi: 10.1007/s00066-011-2186-x. Epub 2011 Apr 26. Strahlenther Onkol. 2011. PMID: 21533760
-
[Current role for induction chemotherapy in head and neck tumors].Laryngorhinootologie. 2008 Apr;87(4):237-43; discussion 244. doi: 10.1055/s-2007-995588. Laryngorhinootologie. 2008. PMID: 18365986 Review. German.
-
[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial].Bull Cancer. 1995 Dec;82(12):1044-51. Bull Cancer. 1995. PMID: 8745671 Review. French.
Cited by
-
[Survival improvement of a unicentric overall population in 20 years: 1038 patients with oral and oropharyngeal squamous cell cancer 1983-2004].Mund Kiefer Gesichtschir. 2007 Nov;11(5):267-83. doi: 10.1007/s10006-007-0077-1. Epub 2007 Sep 25. Mund Kiefer Gesichtschir. 2007. PMID: 17899225 German.
-
Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.Oral Maxillofac Surg. 2009 Jun;13(2):87-93. doi: 10.1007/s10006-009-0159-3. Oral Maxillofac Surg. 2009. PMID: 19430823 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical